本文選題：腰背肌筋膜炎 + 寒濕瘀阻證��； 參考：《重慶醫(yī)學(xué)》2017年11期

【摘要】：目的評價腰痛膠囊+復(fù)方南星止痛膏和美洛昔康+吡羅昔康凝膠的中西醫(yī)方案治療腰背肌筋膜炎寒濕瘀阻證的臨床療效。方法選取2014年6月至2015年12月該院收治的腰背肌筋膜炎寒濕瘀阻證患者170例,分為觀察組和對照組,每組85例。對照組采用美洛昔康膠囊+吡羅昔康凝膠;觀察組采用腰痛膠囊+復(fù)方南星止痛膏;療程為21d,療程結(jié)束后進(jìn)行20周的隨訪。記錄治療1~10d、14d、17d、21d,隨訪4周、8周、12周、16周和20周視覺模擬評分法(VAS)評分,治療前后日本骨科協(xié)會下腰痛評價表(JOA)、身體損傷指數(shù)評定量表(PⅡ)和寒濕瘀阻證情況;檢測治療前后血栓素B2(TXB2)、6-酮前列腺素F_la(6-Keto-PGF_la)水平。結(jié)果觀察組疾病療效和中醫(yī)證候療效均優(yōu)于對照組(P0.05)。對照組和觀察組在21d的觀察周期中VAS評分均呈下降趨勢(P0.05)。在20周的隨訪期間,對照組VAS評分呈逐漸升高趨勢(P0.05);觀察組在治療5~10d、14d、17d、21d,隨訪4周、8周、12周、16周、20周VAS評分均低于對照組(P0.01)。治療后觀察組JOA各維度評分和總分均低于對照組(P0.01),治療后PⅡ各維度評分和總分均低于對照組(P0.01)。治療后觀察組TXB2水平低于對照組,6-Keto-PGF_la水平高于對照組(P0.01)。觀察組復(fù)發(fā)率為17.95%低于對照組的46.75%(χ2=14.712,P0.01)。結(jié)論腰痛膠囊聯(lián)合復(fù)方南星止痛膏治療腰背肌筋膜炎近期能顯著改善患者下腰痛,提高腰的活動范圍,恢復(fù)其功能;遠(yuǎn)期能穩(wěn)定病情,減少復(fù)發(fā)。
[Abstract]:Objective to evaluate the clinical effect of compound Nanxing Zhitong Ointment and meloxicam Piroxicam Gel in the treatment of cold dampness and stasis syndrome of lumbar dorsal myofascitis. Methods from June 2014 to December 2015, 170 patients with cold, dampness and stasis syndrome of lumbar dorsal myofascitis were divided into observation group and control group with 85 cases in each group. The control group was treated with Piroxicam gel of meloxicam capsule and the observation group with compound Nanxing analgesic paste of Yaotong capsule for 21 days and followed up for 20 weeks after the end of the course of treatment. The visual analogue score (VAS) was recorded after 4 weeks, 8 weeks, 12 weeks, 16 weeks and 20 weeks after treatment. Before and after treatment, JOAA, body injury index rating scale (P 鈪，

本文編號：2040280